Company: PENG
Filing Date: 2025-08-27
Form Type: S-3ASR
Source: 0001616533-25-000054
Chunk: 11

Company: Penguin Solutions, Inc.
Filing Date: 2025-08-27
Form: S-3ASR
Chunk 11
---
 State of Delaware in the United States, resulting in Penguin Solutions, Inc., a Delaware corporation, becoming our publicly traded parent company (the “U.S. Domestication”). We are the successor issuer to Penguin Solutions Cayman. The U.S. Domestication was approved by the shareholders of Penguin Solutions Cayman and effected via a court-sanctioned scheme of arrangement under Cayman Islands law, pursuant to which each ordinary share of Penguin Solutions Cayman was exchanged for one share of our common stock, and each convertible preferred share of Penguin Solutions Cayman was exchanged for one share of our convertible preferred stock. Additional information about the U.S. Domestication was included in the Company’s current report on Form 8-K12B, filed with the SEC on June 30, 2025.

Our principal executive offices are located at 1390 McCarthy Boulevard, Milpitas, California 95035, and our telephone number is (510) 623-1231. Our website address is https://www.penguinsolutions.com . The information on, or that can be accessed through, our website is not part of this prospectus and is not incorporated by reference herein. We have included our website address as an inactive textual reference only.

<div align='center'>8</div>

### RISK FACTORS
Investment in any securities offered pursuant to this prospectus and any applicable prospectus supplement involves risks. You should carefully consider the risk factors incorporated by reference to our most recent Annual Report on Form 10-K and any subsequent Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q or Current Reports on Form 8-K we file after the date of this prospectus, and all other information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the Exchange Act, and the risk factors and other information contained in any applicable prospectus supplement and any applicable free writing prospectus before making a decision about investing in our securities. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.

<div align='center'>9</div>

### USE OF PROCEEDS
We will not receive any of the proceeds from the sale of common stock being offered by the Selling Securityholder.

However, we have agreed to pay certain registration expenses, other than underwriting discounts and commissions and applicable transfer taxes, in connection with offerings by the Selling Securityholder, including, without limitation, all registration fees, printers and accounting fees, and fees and disbursements of our counsel